All Stories

  1. Sex differences in venous thromboembolism outcomes: findings from the GARFIELD-VTE registry

    Article • European Journal of Internal Medicine, February 2026, Elsevier

    Professor Zhi-Cheng JING

  2. Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension

    Article • American Review of Respiratory Disease, January 2026, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  3. Hereditary pulmonary veno-occlusive disease with a distinctive rare genetic pattern

    Article • Thorax, July 2025, BMJ

    Professor Zhi-Cheng JING

  4. Evaluation of Safety and Pharmacokinetics of DDCI-01, a Phosphodiesterase Type 5 Inhibitor, in Healthy Participants

    Article • Clinical Pharmacokinetics, March 2025, Springer Science + Business Media

    Professor Zhi-Cheng JING

  5. Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF

    Article • Open Heart, February 2025, BMJ

    Professor Zhi-Cheng JING

  6. Relaxin Mimetic in Pulmonary Hypertension Associated with Left Heart Disease: Design and Rationale of Re-PHIRE

    Article • ESC Heart Failure, January 2025, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  7. Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

    Article • Journal of Molecular and Cellular Cardiology, December 2024, Elsevier

    Professor Zhi-Cheng JING

  8. Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, September 2024, Elsevier

    Professor Zhi-Cheng JING

  9. Identification of Noncoding Functional Regulatory Variants of STIM1 Gene in Idiopathic Pulmonary Arterial Hypertension

    Article • Hypertension, September 2024, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  10. Treatment algorithm for pulmonary arterial hypertension

    Article • European Respiratory Journal, August 2024, European Respiratory Society (ERS)

    Professor Olivier SITBON, Professor Zhi-Cheng JING

  11. Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

    Article • JACC Asia, August 2024, Elsevier

    Professor Zhi-Cheng JING

  12. Association between coronary artery stenosis and myocardial injury in patients with acute pulmonary embolism: A case-control study

    Article • Chinese Medical Journal, July 2024, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  13. Development and external validation of a nomogram for predicting short-term prognosis in patients with acute pulmonary embolism

    Article • International Journal of Cardiology, July 2024, Elsevier

    Professor Zhi-Cheng JING

  14. Identification of Prostaglandin I 2 Synthase Rare Variants in Patients With Williams Syndrome and Severe Peripheral Pulmonary Stenosis

    Article • Journal of the American Heart Association, May 2024, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  15. Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension

    Article • European Journal of Pharmacology, May 2024, Elsevier

    Professor Zhi-Cheng JING

  16. The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension

    Article • European Respiratory Journal, May 2024, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  17. Combined guidance of fluoroscopy and transthoracic echocardiography for endomyocardial biopsy

    Article • European Journal of Internal Medicine, April 2024, Elsevier

    Professor Zhi-Cheng JING

  18. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

    Article • The Lancet Respiratory Medicine, April 2024, Elsevier

    Professor Zhi-Cheng JING

  19. Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study

    Article • Hypertension, February 2024, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  20. Publisher Correction: Pulmonary hypertension

    Article • Nature Reviews Disease Primers, January 2024, Springer Science + Business Media

    Professor Zhi-Cheng JING

  21. Pulmonary hypertension

    Article • Nature Reviews Disease Primers, January 2024, Springer Science + Business Media

    Professor Zhi-Cheng JING

  22. IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension

    Article • Pulmonary Circulation, January 2024, Wiley

    Professor Zhi-Cheng JING

  23. The Global Burden of Pulmonary Arterial Hypertension from 1990 to 2021: Systematic Analysis for the Global Burden of Disease Study 2021

    Article • January 2024, Elsevier

    Professor Zhi-Cheng JING

  24. Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure

    Article • European Heart Journal, December 2023, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  25. Prognostic value of plasma IgG N-glycome traits in patients with pulmonary arterial hypertension: an observational cohort study

    Article • December 2023, openRxiv

    Professor Zhi-Cheng JING

  26. High-level clinical research promotes the development of risk stratification for pulmonary arterial hypertension

    Article • Chinese Science Bulletin (Chinese Version), December 2023, Science China Press., Co. Ltd.

    Professor Zhi-Cheng JING

  27. MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension

    Article • Vascular Pharmacology, December 2023, Elsevier

    Professor Zhi-Cheng JING

  28. Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry

    Article • Journal of Thrombosis and Thrombolysis, November 2023, Springer Science + Business Media

    Professor Zhi-Cheng JING

  29. Echocardiography combined with Mayo staging enhances the identification of early mortality risk in patients with light-chain cardiac amyloidosis

    Article • Chinese Science Bulletin (Chinese Version), October 2023, Science China Press., Co. Ltd.

    Professor Zhi-Cheng JING

  30. Heart Rate Response Predicts 6-Minutes Walking Distance in Pulmonary Arterial Hypertension

    Article • The American Journal of Cardiology, October 2023, Elsevier

    Professor Zhi-Cheng JING

  31. Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group

    Article • Pulmonary Circulation, October 2023, Wiley

    Professor Zhi-Cheng JING

  32. Human Plasma IgG N -Glycome Profiles Reveal a Proinflammatory Phenotype in Chronic Thromboembolic Pulmonary Hypertension

    Article • Hypertension, September 2023, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  33. Congenital thrombophilia in East-Asian venous thromboembolism population: a systematic review and meta-analysis

    Article • Research and Practice in Thrombosis and Haemostasis, August 2023, Elsevier

    Professor Zhi-Cheng JING

  34. Percutaneous transluminal pulmonary angioplasty for Takayasu arteritis‐associated pulmonary hypertension: A single‐arm meta‐analysis

    Article • Catheterization and Cardiovascular Interventions, July 2023, Wiley

    Professor Zhi-Cheng JING

  35. Vaccination against coronavirus disease 2019 in patients with pulmonary hypertension: A national prospective cohort study

    Article • Chinese Medical Journal, July 2023, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  36. Clonal Hematopoiesis of Indeterminate Potential in Patients with Chronic Thromboembolic Pulmonary Hypertension

    Article • May 2023, openRxiv

    Professor Zhi-Cheng JING

  37. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction

    Article • The Oncologist, May 2023, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  38. Single-cell analysis of peripheral blood from high-altitude pulmonary hypertension patients identifies a distinct monocyte phenotype

    Article • Nature Communications, March 2023, Springer Science + Business Media

    Professor Zhi-Cheng JING

  39. Prognostic Value of Preoperative Assessment of Left Ventricular Function in Patients Undergoing Percutaneous Coronary Intervention

    Article • Reviews in Cardiovascular Medicine, March 2023, IMR Press

    Professor Zhi-Cheng JING

  40. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

    Article • Thrombosis Research, February 2023, Elsevier

    Professor Zhi-Cheng JING

  41. Human Plasma Immunoglobulin G N-Glycome Profiles Reveal a Pro-Inflammatory Phenotype in Chronic Thromboembolic Pulmonary Hypertension: A Cross-Sectional Study of Two Independent Cohorts

    Article • January 2023, Elsevier

    Professor Zhi-Cheng JING

  42. Building a modern six-dimensional biobank fosters the future of precision medicine

    Article • Science Bulletin, December 2022, Elsevier

    Professor Zhi-Cheng JING

  43. Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day

    Article • Journal of Thrombosis and Haemostasis, October 2022, Wiley

    Professor Edeghonghon Olayemi, Luis Jara-Palomares, Professor Zhi-Cheng JING

  44. Native T1 Mapping-Based Radiomics for Noninvasive Prediction of the Therapeutic Effect of Pulmonary Arterial Hypertension

    Article • Diagnostics, October 2022, MDPI AG

    Professor Zhi-Cheng JING

  45. Reply

    Article • JACC Asia, October 2022, Elsevier

    Professor Zhi-Cheng JING

  46. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

    Article • Clinical Research in Cardiology, September 2022, Springer Science + Business Media

    Professor Zhi-Cheng JING

  47. Statin therapy in venous thromboembolism: How far from primary and secondary prevention?

    Article • Journal of Thrombosis and Haemostasis, August 2022, Elsevier

    Professor Zhi-Cheng JING

  48. Protein O-GlcNAcylation in cardiovascular diseases

    Article • Acta Pharmacologica Sinica, July 2022, Springer Science + Business Media

    Professor Zhi-Cheng JING

  49. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

    Article • Journal of Clinical Medicine, July 2022, MDPI AG

    Professor Zhi-Cheng JING

  50. 18β-Glycyrrhetinic Acid Ameliorates Endoplasmic Reticulum Stress-Induced Inflammation in Pulmonary Arterial Hypertension Through PERK/eIF2α/NF-κB Signaling

    Article • The Chinese Journal of Physiology, July 2022, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  51. Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility

    Article • Hypertension, July 2022, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  52. Prevalence, Genetic Background, and Clinical Phenotype of Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension

    Article • JACC Asia, June 2022, Elsevier

    Professor Zhi-Cheng JING

  53. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, April 2022, Elsevier

    Professor Zhi-Cheng JING

  54. Experimental animal models of pulmonary hypertension: Development and challenges

    Article • Animal Models and Experimental Medicine, March 2022, Wiley

    Professor Zhi-Cheng JING

  55. Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension

    Article • Journal of Clinical Medicine, March 2022, MDPI AG

    Professor Zhi-Cheng JING

  56. 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy

    Article • Chinese Medical Journal, March 2022, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  57. Beyond medications: is pulmonary artery denervation the answer for pulmonary arterial hypertension?

    Article • AsiaIntervention, March 2022, Europa Digital & Publishing

    Professor Zhi-Cheng JING

  58. Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study

    Article • Frontiers in Public Health, January 2022, Frontiers

    Professor Zhi-Cheng JING

  59. Subendocardial Involvement as an Underrecognized Cardiac MRI Phenotype in Myocarditis

    Article • Radiology, January 2022, Radiological Society of North America (RSNA)

    Professor Zhi-Cheng JING

  60. Coronavirus Disease Vaccination in Patients with Pulmonary Hypertension: A National Prospective Cohort Study

    Article • SSRN Electronic Journal, January 2022, Elsevier

    Professor Zhi-Cheng JING

  61. Association between Coronary Artery Stenosis and Myocardial Injury in Patients with Acute Pulmonary Embolism: A Case-Control Study

    Article • SSRN Electronic Journal, January 2022, Elsevier

    Professor Zhi-Cheng JING

  62. Betaine Attenuates Pulmonary Arterial Hypertension By Regulating PERK-eIF2α Signaling Pathway

    Article • SSRN Electronic Journal, January 2022, Elsevier

    Professor Zhi-Cheng JING

  63. Corrigendum to “Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE” [Thromb. Res. 2021 May;201:63–72]

    Article • Thrombosis Research, January 2022, Elsevier

    Professor Zhi-Cheng JING

  64. Corrigendum: Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension

    Article • Frontiers in Pharmacology, December 2021, Frontiers

    Professor Zhi-Cheng JING

  65. Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease

    Article • Acta Pharmacologica Sinica, November 2021, Springer Science + Business Media

    Professor Zhi-Cheng JING

  66. Implication of proliferation gene biomarkers in pulmonary hypertension

    Article • Animal Models and Experimental Medicine, November 2021, Wiley

    Professor Zhi-Cheng JING

  67. Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension

    Article • Frontiers in Pharmacology, November 2021, Frontiers

    Professor Zhi-Cheng JING

  68. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data

    Article • BMJ, October 2021, BMJ

    Professor Zhi-Cheng JING

  69. Retrospective Study of Critically Ill COVID-19 Patients With and Without Extracorporeal Membrane Oxygenation Support in Wuhan, China

    Article • Frontiers in Medicine, October 2021, Frontiers

    Professor Zhi-Cheng JING

  70. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

    Article • The Journal of Heart and Lung Transplantation, October 2021, Elsevier

    Professor Zhi-Cheng JING

  71. Clinical features and survival in Takayasu’s arteritis-associated pulmonary hypertension: a nationwide study

    Article • European Heart Journal, September 2021, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  72. Standard Operation Procedure of Percutaneous Endomyocardial Biopsy in Peking Union Medical College Hospital

    Article • Cardiology Discovery, July 2021, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  73. Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension

    Article • July 2021, Research Square

    Professor Zhi-Cheng JING

  74. Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome

    Article • Frontiers in Physiology, June 2021, Frontiers

    Professor Zhi-Cheng JING

  75. Chinese Guideline on the Primary Prevention of Cardiovascular Diseases

    Article • Cardiology Discovery, June 2021, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  76. Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension

    Article • Frontiers in Cardiovascular Medicine, May 2021, Frontiers

    Professor Zhi-Cheng JING

  77. Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE

    Article • Thrombosis Research, May 2021, Elsevier

    Professor Zhi-Cheng JING

  78. A Personalized Pulmonary Circulation Model to Non-Invasively Calculate Fractional Flow Reserve for Artery Stenosis Detection

    Article • IEEE Transactions on Biomedical Engineering, January 2021, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Zhi-Cheng JING

  79. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension

    Article • Science Advances, December 2020, American Association for the Advancement of Science

    Professor Zhi-Cheng JING

  80. Association between congenital thrombophilia and outcomes in pulmonary embolism patients

    Article • Blood Advances, December 2020, American Society of Hematology

    Professor Zhi-Cheng JING

  81. Generation of an induced pluripotent stem cell line (PUMCHi006-A) derived from a patient with pulmonary arterial hypertension carrying heterozygous c.1339 G > A mutation in PTGIS gene

    Article • Stem Cell Research, December 2020, Elsevier

    Professor Zhi-Cheng JING

  82. Inflammation and cardiovascular diseases

    Article • Chronic Diseases and Translational Medicine, December 2020, Elsevier

    Professor Zhi-Cheng JING

  83. Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension

    Article • Frontiers in Medicine, November 2020, Frontiers

    Professor Zhi-Cheng JING

  84. The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population

    Article • International Journal of Cardiology, November 2020, Elsevier

    Professor Zhi-Cheng JING

  85. How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?

    Article • Expert Opinion on Pharmacotherapy, October 2020, Taylor & Francis

    Professor Zhi-Cheng JING

  86. Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension

    Article • Expert Review of Cardiovascular Therapy, September 2020, Taylor & Francis

    Professor Zhi-Cheng JING

  87. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

    Article • BMC Cardiovascular Disorders, July 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  88. Derivation of an induced pluripotent stem cell line (PUMCHi003-A) from a patient with pulmonary arterial hypertension carrying heterozygous mutation in PTGIS gene

    Article • Stem Cell Research, July 2020, Elsevier

    Professor Zhi-Cheng JING

  89. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

    Article • Journal of Thrombosis and Thrombolysis, June 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  90. Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension

    Article • European Respiratory Journal, June 2020, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  91. Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • JAMA Cardiology, June 2020, American Medical Association (AMA)

    Professor Zhi-Cheng JING

  92. Protective effects of isorhamnetin on pulmonary arterial hypertension: in vivo and in vitro studies

    Article • Phytotherapy Research, May 2020, Wiley

    Professor Zhi-Cheng JING

  93. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis

    Article • Current Rheumatology Reports, May 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  94. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

    Article • Circulation, May 2020, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  95. Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases

    Article • Frontiers in Pharmacology, May 2020, Frontiers

    Professor Zhi-Cheng JING

  96. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions

    Article • Journal of the American College of Cardiology, May 2020, Elsevier

    Prof./Phd Ganna D Radchenko, Professor Zhi-Cheng JING

  97. Micro RNA ‐483 amelioration of experimental pulmonary hypertension

    Article • EMBO Molecular Medicine, April 2020, EMBO

    Professor Zhi-Cheng JING

  98. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

    Article • European Heart Journal, March 2020, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  99. Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Professor Zhi-Cheng JING

  100. The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS)

    Article • European Heart Journal, December 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  101. Comparative analysis of the plasma metabolomics in rodent models of pulmonary hypertension and patients with IPAH shows different metabolic signatures

    Article • September 2019, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  102. Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway

    Article • Chemico-Biological Interactions, September 2019, Elsevier

    Professor Zhi-Cheng JING

  103. Association Between High FSH, Low Progesterone, and Idiopathic Pulmonary Arterial Hypertension in Women of Reproductive Age

    Article • American Journal of Hypertension, August 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  104. Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism

    Article • Cardiovascular Toxicology, August 2019, Springer Science + Business Media

    Professor Zhi-Cheng JING

  105. Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients

    Article • American Journal of Hypertension, July 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  106. Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients

    Article • Thrombosis and Haemostasis, June 2019, Thieme Publishing Group

    Professor Zhi-Cheng JING

  107. Adventitial Cell Atlas of wt (Wild Type) and ApoE (Apolipoprotein E)-Deficient Mice Defined by Single-Cell RNA Sequencing

    Article • Arteriosclerosis Thrombosis and Vascular Biology, June 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  108. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation

    Article • JAMA Cardiology, June 2019, American Medical Association (AMA)

    Dr. Kenji Sadamatsu, Professor Dmitry Zateyshchikov, Dr Carlos H. Del Carlo, Professor Zhi-Cheng JING

  109. Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation

    Article • AJP Lung Cellular and Molecular Physiology, May 2019, American Physiological Society

    Professor Zhi-Cheng JING

  110. Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension

    Article • Arteriosclerosis Thrombosis and Vascular Biology, April 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  111. Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor

    Article • Arteriosclerosis Thrombosis and Vascular Biology, March 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  112. Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure

    Article • The Clinical Respiratory Journal, February 2019, Wiley

    Professor Zhi-Cheng JING

  113. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

    Article • Journal of the American Heart Association, February 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING, Dr. Kenji Sadamatsu, Professor Dmitry Zateyshchikov, Filipa Costa, Dr Carlos H. Del Carlo

  114. Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis

    Article • Internal and Emergency Medicine, January 2019, Springer Science + Business Media

    Professor Zhi-Cheng JING

  115. Risk stratification and medical therapy of pulmonary arterial hypertension

    Article • European Respiratory Journal, January 2019, European Respiratory Society (ERS)

    Professor Nazzareno Galie, Prof Tomas Pulido, Professor Zhi-Cheng JING

  116. Paediatric Pulmonary Arterial Hypertension in China During 2006-18: Insights from a Longitudinal Registry Study

    Article • SSRN Electronic Journal, January 2019, Elsevier

    Professor Zhi-Cheng JING

  117. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry

    Article • Thrombosis and Haemostasis, December 2018, Thieme Publishing Group

    Professor Dmitry Zateyshchikov, Professor Zhi-Cheng JING

  118. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, December 2018, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  119. 3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis

    Article • American Journal of Hypertension, December 2018, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  120. Percutaneous coronary intervention equates to placebo procedure in stable angina?

    Article • Journal of Thoracic Disease, December 2018, AME Publishing Company

    Professor Zhi-Cheng JING

  121. When REVEAL meets AMBITION, does it reveal more?

    Article • The Journal of Heart and Lung Transplantation, December 2018, Elsevier

    Professor Zhi-Cheng JING

  122. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis

    Article • Autoimmunity Reviews, October 2018, Elsevier

    Professor Zhi-Cheng JING

  123. EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    Article • CHEST Journal, October 2018, Elsevier

    Professor Zhi-Cheng JING

  124. Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension

    Article • Circulation, July 2018, Wolters Kluwer Health

    Professor Allan Lawrie, Professor Zhi-Cheng JING

  125. Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice

    Article • Journal of Experimental Medicine, July 2018, Rockefeller University Press

    Professor Zhi-Cheng JING

  126. Impact of Pituitary–Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men

    Article • Hypertension, July 2018, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  127. Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline

    Article • May 2018, Springer Science + Business Media

    Professor Zhi-Cheng JING

  128. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis

    Article • Journal of Cardiology, May 2018, Elsevier

    Professor Zhi-Cheng JING

  129. IgG4-related disease of pulmonary artery causing pulmonary hypertension

    Article • Medicine, May 2018, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  130. Whole-exome sequencing improves genetic testing accuracy in pulmonary artery hypertension

    Article • February 2018, SAGE Publications

    Professor Zhi-Cheng JING

  131. PTGIS is a Novel Susceptibility Gene for Pulmonary Arterial Hypertension

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Professor Zhi-Cheng JING

  132. Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, December 2017, American Thoracic Society

    Professor Zhi-Cheng JING, Professor Allan Lawrie

  133. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  134. Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression

    Article • American Review of Respiratory Disease, October 2017, American Thoracic Society

    Professor Zhi-Cheng JING

  135. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

    Article • The Lancet Respiratory Medicine, October 2017, Elsevier

    Professor Zhi-Cheng JING

  136. Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study

    Article • September 2017, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  137. Reply to “Comment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertension”

    Article • International Journal of Cardiology, July 2017, Elsevier

    Professor Zhi-Cheng JING

  138. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report

    Article • American Review of Respiratory Disease, June 2017, American Thoracic Society

    Professor Zhi-Cheng JING

  139. A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  140. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study

    Article • The Journal of Heart and Lung Transplantation, May 2017, Elsevier

    Professor Zhi-Cheng JING

  141. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension

    Article • Drug Design Development and Therapy, April 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  142. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension

    Article • BMC Pulmonary Medicine, February 2017, Springer Science + Business Media

    Professor Zhi-Cheng JING

  143. Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension

    Article • International Journal of Cardiology, February 2017, Elsevier

    Professor Zhi-Cheng JING

  144. Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells

    Article • International Journal of Medical Sciences, January 2017, Ivyspring International Publisher

    Professor Zhi-Cheng JING

  145. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension

    Article • Clinical Cardiology, November 2016, Wiley

    Professor Zhi-Cheng JING

  146. Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension

    Article • International Journal of Cardiology, November 2016, Elsevier

    Professor Zhi-Cheng JING

  147. Optical coherence tomography for hypertensive pulmonary vasculature

    Article • International Journal of Cardiology, November 2016, Elsevier

    Professor Zhi-Cheng JING

  148. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study

    Article • BMC Cardiovascular Disorders, October 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  149. Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling

    Article • Current Pharmaceutical Design, October 2016, Bentham Science Publishers

    Professor Zhi-Cheng JING

  150. GW27-e0047 Characteristics of Cardiopulmonary Exercise Tests in Patients with Borderline Pulmonary Arterial Pressure

    Article • Journal of the American College of Cardiology, October 2016, Elsevier

    Professor Zhi-Cheng JING

  151. Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, September 2016, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  152. Clinical characteristics of pulmonary hypertension in bronchiectasis

    Article • Frontiers of Medicine, September 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  153. Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension

    Article • CHEST Journal, August 2016, Elsevier

    Professor Zhi-Cheng JING

  154. Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension

    Article • Journal of Molecular Medicine, May 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  155. BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease

    Article • International Journal of Cardiology, May 2016, Elsevier

    Professor Zhi-Cheng JING

  156. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

    Article • The Lancet Respiratory Medicine, May 2016, Elsevier

    Professor Zhi-Cheng JING

  157. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison

    Article • Heart Asia, May 2016, BMJ

    Professor Zhi-Cheng JING

  158. A global view of pulmonary hypertension

    Article • The Lancet Respiratory Medicine, April 2016, Elsevier

    Professor Rogerio Souza, Professor Zhi-Cheng JING

  159. Shape of the Pulmonary Artery Doppler-Flow Profile Predicts the Hemodynamics of Pulmonary Hypertension Caused by Left-Sided Heart Disease

    Article • Clinical Cardiology, March 2016, Wiley

    Professor Zhi-Cheng JING

  160. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, March 2016, Elsevier

    Professor Zhi-Cheng JING

  161. Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

    Article • European Heart Journal Supplements, February 2016, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  162. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

    Article • The Lancet Respiratory Medicine, February 2016, Elsevier

    Professor Olivier SITBON, Dr. Erika Berman Rosenzweig, Professor Zhi-Cheng JING

  163. Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis

    Article • Hypertension Research, January 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  164. Review Common genetic risk factors of venous thromboembolism in Western and Asian populations

    Article • Genetics and Molecular Research, January 2016, Genetics and Molecular Research

    Professor Zhi-Cheng JING

  165. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)

    Article • International Journal of Cardiology, January 2016, Elsevier

    Professor Zhi-Cheng JING

  166. The limits of oral therapy in pulmonary arterial hypertension management

    Article • Therapeutics and Clinical Risk Management, November 2015, Taylor & Francis

    Professor Zhi-Cheng JING

  167. GW26-e4721 Circulating Progesterone and Hemodynamic Parameters in Men with Idiopathic Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, October 2015, Elsevier

    Professor Zhi-Cheng JING

  168. GW26-e4380 Screening and Differences for Glycolytic Metabolism Related Genes Between Two Ventricles in Monocmtaline Induced Pulmonary Arterial Hypertension Rats

    Article • Journal of the American College of Cardiology, October 2015, Elsevier

    Professor Zhi-Cheng JING

  169. GW26-e4723 Serum Concentrations of Sex Hormones in Patients with Idiopathic Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, October 2015, Elsevier

    Professor Zhi-Cheng JING

  170. GW26-e4818 The L-carnitine Ameliorates Pulmonary Arterial Hypertension by Improving Energy Metabolism Dysfunction of Right Ventricular Failure

    Article • Journal of the American College of Cardiology, October 2015, Elsevier

    Professor Zhi-Cheng JING

  171. Research update for articles published in EJCI in 2013

    Article • European Journal of Clinical Investigation, September 2015, Wiley

    Professor Zhi-Cheng JING

  172. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis

    Article • American Heart Journal, July 2015, Elsevier

    Professor Zhi-Cheng JING

  173. Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension

    Article • Hypertension Research, March 2015, Springer Science + Business Media

    Professor Zhi-Cheng JING

  174. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

    Article • European Respiratory Journal, January 2015, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  175. Bosentan up-front or sequential add-on combination treatment for pulmonary arterial hypertension: long-term effects and prognosis

    Article • Academic Journal of Second Military Medical University, January 2015, China Science Publishing & Media Ltd.

    Professor Zhi-Cheng JING

  176. Isoprostane as a promising biomarker in pulmonary arterial hypertension: Preanalytical and analytical viewpoints. Response to letter to the editor

    Article • International Journal of Cardiology, December 2014, Elsevier

    Professor Zhi-Cheng JING

  177. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study

    Article • International Journal of Cardiology, November 2014, Elsevier

    Professor Zhi-Cheng JING

  178. Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • The American Journal of Cardiology, November 2014, Elsevier

    Professor Zhi-Cheng JING

  179. Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension

    Article • October 2014, Springer Science + Business Media

    Professor Zhi-Cheng JING

  180. Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension

    Article • International Journal of Cardiology, August 2014, Elsevier

    Professor Zhi-Cheng JING

  181. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients

    Article • European Respiratory Journal, May 2014, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  182. BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension

    Article • Lung, April 2014, Springer Science + Business Media

    Professor Zhi-Cheng JING

  183. SURVIVAL OF PATIENTS WITH REPAIRED CHD-PAH IN THE MODERN MANAGEMENT ERA

    Article • Journal of the American College of Cardiology, April 2014, Elsevier

    Professor Zhi-Cheng JING

  184. Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

    Article • CHEST Journal, March 2014, Elsevier

    Professor Zhi-Cheng JING

  185. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies

    Article • Thrombosis Journal, December 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  186. Updated Treatment Algorithm of Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, December 2013, Elsevier

    Professor Zhi-Cheng JING

  187. Pediatric Pulmonary Arterial Hypertension

    Article • Current Hypertension Reports, October 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  188. Epidemiology of Pulmonary Arterial Hypertension

    Article • Current Hypertension Reports, October 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  189. Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study

    Article • CHEST Journal, October 2013, Elsevier

    Professor Zhi-Cheng JING

  190. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study)

    Article • CHEST Journal, September 2013, Elsevier

    Professor Zhi-Cheng JING

  191. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Rogerio Souza, Professor Olivier SITBON, Professor Zhi-Cheng JING

  192. Antioxidant effects of phosphodiesterase-5 inhibitors: reply

    Article • Cardiovascular Research, August 2013, European Society of Cardiology

    Professor Zhi-Cheng JING

  193. Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension

    Article • European Journal of Clinical Investigation, August 2013, Wiley

    Professor Zhi-Cheng JING

  194. Riociguat for the Treatment of Pulmonary Arterial Hypertension

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2013, New England Journal of Medicine (NEJM/MMS)

    Horst Olschewski, Professor Zhi-Cheng JING

  195. Complexities of oestradiol pharmacology in pulmonary arterial hypertension

    Article • European Respiratory Journal, May 2013, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  196. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension

    Article • Cardiovascular Research, May 2013, European Society of Cardiology

    Professor Zhi-Cheng JING

  197. Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

    Article • Circulation, February 2013, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  198. Lower Socioeconomic Status Is Associated with Worse Outcomes in Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, February 2013, American Thoracic Society

    Professor Zhi-Cheng JING

  199. BMPR2Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial Hypertension

    Article • Circulation Cardiovascular Genetics, October 2012, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  200. THE BASELINE CHARACTERISTICS AND SURVIVAL OF CHINESE PATIENTS WITH CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION

    Article • Heart, October 2012, BMJ

    Professor Zhi-Cheng JING

  201. Oestradiol ameliorates monocrotaline pulmonary hypertensionviaNO, prostacyclin and endothelin-1 pathways

    Article • European Respiratory Journal, August 2012, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  202. Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • The American Journal of Cardiology, August 2012, Elsevier

    Professor Zhi-Cheng JING

  203. Usefulness of Intravenous Adenosine in Idiopathic Pulmonary Arterial Hypertension as a Screening Agent for Identifying Long-Term Responders to Calcium Channel Blockers

    Article • The American Journal of Cardiology, June 2012, Elsevier

    Professor Zhi-Cheng JING

  204. Clinical features of paediatric pulmonary hypertension: a registry study

    Article • The Lancet, February 2012, Elsevier

    Professor Damien Bonnet, Professor Zhi-Cheng JING, Rolf Berger

  205. Prolonged QRS Duration

    Article • CHEST Journal, February 2012, Elsevier

    Professor Zhi-Cheng JING

  206. High-Altitude Pulmonary Hypertension

    Article • January 2012, Karger Publishers

    Professor Zhi-Cheng JING

  207. Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries

    Article • January 2012, Karger Publishers

    Professor Zhi-Cheng JING

  208. Assessment of right heart function in the patients with pulmonary arterial hypertension using 2D strain echocardiography

    Article • Heart, October 2011, BMJ

    Professor Zhi-Cheng JING

  209. Evaluation of two-dimensional strain echocardiography in quantifying right ventricular function in patients with pulmonary hypertension

    Article • Heart, October 2011, BMJ

    Professor Zhi-Cheng JING

  210. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

    Article • Journal of Translational Medicine, September 2011, Springer Science + Business Media

    Professor Zhi-Cheng JING

  211. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study

    Article • Heart, September 2011, BMJ

    Professor Zhi-Cheng JING

  212. Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era

    Article • CHEST Journal, August 2011, Elsevier

    Professor Zhi-Cheng JING

  213. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients

    Article • European Respiratory Journal, July 2011, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  214. Vardenafil in Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, June 2011, American Thoracic Society

    Professor Zhi-Cheng JING

  215. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats

    Article • International Journal of Molecular Medicine, September 2010, Spandidos Publications

    Professor Zhi-Cheng JING

  216. Iloprost—different indications and different national experiences in treating pulmonary hypertension

    Article • Clinical Research in Cardiology Supplements, September 2010, Springer Science + Business Media

    Professor Zhi-Cheng JING

  217. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

    Article • European Respiratory Journal, June 2010, European Respiratory Society (ERS)

    Professor Rogerio Souza, Professor Olivier SITBON, Professor Zhi-Cheng JING

  218. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension

    Article • The Journal of Heart and Lung Transplantation, February 2010, Elsevier

    Professor Zhi-Cheng JING

  219. Pulmonary function testing in patients with pulmonary arterial hypertension

    Article • Respiratory Medicine, August 2009, Elsevier

    Professor Zhi-Cheng JING

  220. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension

    Article • Hypertension Research, July 2009, Springer Science + Business Media

    Professor Zhi-Cheng JING

  221. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study

    Article • Heart, June 2009, BMJ

    Professor Zhi-Cheng JING

  222. Updated Clinical Classification of Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, June 2009, Elsevier

    Professor Rogerio Souza, Professor Zhi-Cheng JING

  223. High-altitude pulmonary hypertension

    Article • European Respiratory Review, March 2009, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  224. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, February 2009, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  225. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension

    Article • Chinese Medical Journal, December 2008, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  226. Registry and Survival Study in Chinese Patients With Idiopathic and Familial Pulmonary Arterial Hypertension

    Article • CHEST Journal, August 2007, Elsevier

    Professor Zhi-Cheng JING

  227. Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATPchannel

    Article • European Journal of Heart Failure, January 2007, Wiley

    Professor Zhi-Cheng JING

  228. Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers

    Article • Journal of the American College of Cardiology, December 2006, Elsevier

    Professor Zhi-Cheng JING

  229. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion

    Article • Heart, August 2006, BMJ

    Professor Zhi-Cheng JING

  230. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion

    Article • Coronary Artery Disease, August 2006, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  231. Herpes Simplex Virus Type 2 Infection Is a Risk Factor for Hypertension

    Article • Hypertension Research, January 2004, Japanese Society of Hypertension

    Professor Zhi-Cheng JING